Literature DB >> 21833710

A rare case of Visceral leishmaniasis with multiple relapse and multi-drug unresponsive: successfully treated with combination therapy.

Nawin Kumar1, Prabhat Kumar Sinha, Krishna Pandey, Neena Verma, Chandra Shekhar Lal, Alok Ranjan, Rakesh Bihari Verma, Pradeep Das.   

Abstract

CASE: We report a 32-year old relapse case of Visceral leishmaniasis, treated with Paromomycin who belonged from a endemic zone of Bihar state, India. After confirmation, he was treated with Amphotericin B, followed by Liposomal Amphotericin B in full course and even in higher dose. But after each therapy, the patient either did not responded or relapsed after treatment. Ultimately, the patient was successfully treated with combination therapy of Liposomal amphotericin B and Miltefosine without any relapse.
CONCLUSION: The multi-drug unresponsive Visceral leishmaniasis cases could pose a major threat to treatment strategy in the elimination program. In such situation, combination therapy seems to be a better approach that needs to be explored.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21833710     DOI: 10.1007/s11096-011-9544-8

Source DB:  PubMed          Journal:  Int J Clin Pharm


  10 in total

1.  Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic.

Authors:  S Sundar; D K More; M K Singh; V P Singh; S Sharma; A Makharia; P C Kumar; H W Murray
Journal:  Clin Infect Dis       Date:  2000-10       Impact factor: 9.079

2.  Ambisome plus miltefosine for Indian patients with kala-azar.

Authors:  Shyam Sundar; Prabhat Kumar Sinha; Deepak K Verma; Nawin Kumar; Shahnawaj Alam; Krishna Pandey; Poonam Kumari; Vidyanand Ravidas; Jaya Chakravarty; Neena Verma; Jonathan Berman; Hashim Ghalib; Byron Arana
Journal:  Trans R Soc Trop Med Hyg       Date:  2010-12-03       Impact factor: 2.184

3.  Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.

Authors:  Shyam Sundar; Prabhat Kumar Sinha; Madhukar Rai; Deepak Kumar Verma; Kumar Nawin; Shanawwaj Alam; Jaya Chakravarty; Michel Vaillant; Neena Verma; Krishna Pandey; Poonam Kumari; Chandra Shekhar Lal; Rakesh Arora; Bhawna Sharma; Sally Ellis; Nathalie Strub-Wourgaft; Manica Balasegaram; Piero Olliaro; Pradeep Das; Farrokh Modabber
Journal:  Lancet       Date:  2011-01-20       Impact factor: 79.321

4.  Use of amphotericin B in drug-resistant cases of visceral leishmaniasis in north Bihar, India.

Authors:  T K Jha; Y N Giri; T K Singh; S Jha
Journal:  Am J Trop Med Hyg       Date:  1995-06       Impact factor: 2.345

5.  New perspectives on a subclinical form of visceral leishmaniasis.

Authors:  R Badaro; T C Jones; E M Carvalho; D Sampaio; S G Reed; A Barral; R Teixeira; W D Johnson
Journal:  J Infect Dis       Date:  1986-12       Impact factor: 5.226

6.  Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum.

Authors:  Laurence Lachaud; Nathalie Bourgeois; Marie Plourde; Philippe Leprohon; Patrick Bastien; Marc Ouellette
Journal:  Clin Infect Dis       Date:  2009-01-15       Impact factor: 9.079

7.  Leishmania commandeers the host inflammatory response through neutrophils.

Authors:  Ryan C Jochim; Clarissa Teixeira
Journal:  Trends Parasitol       Date:  2009-03-05

Review 8.  The relationship between leishmaniasis and AIDS: the second 10 years.

Authors:  Jorge Alvar; Pilar Aparicio; Abraham Aseffa; Margriet Den Boer; Carmen Cañavate; Jean-Pierre Dedet; Luigi Gradoni; Rachel Ter Horst; Rogelio López-Vélez; Javier Moreno
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

9.  Injectable paromomycin for Visceral leishmaniasis in India.

Authors:  Shyam Sundar; T K Jha; Chandreshwar P Thakur; Prabhat K Sinha; Sujit K Bhattacharya
Journal:  N Engl J Med       Date:  2007-06-21       Impact factor: 91.245

10.  Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.

Authors:  Karin Seifert; F Javier Pérez-Victoria; Marianne Stettler; María P Sánchez-Cañete; Santiago Castanys; Francisco Gamarro; Simon L Croft
Journal:  Int J Antimicrob Agents       Date:  2007-07-12       Impact factor: 5.283

  10 in total
  3 in total

1.  Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin B.

Authors:  Mohammad Asad; Pradyot Bhattacharya; Antara Banerjee; Nahid Ali
Journal:  BMC Infect Dis       Date:  2015-04-17       Impact factor: 3.090

Review 2.  Genetically modified organisms and visceral leishmaniasis.

Authors:  Rudra Chhajer; Nahid Ali
Journal:  Front Immunol       Date:  2014-05-14       Impact factor: 7.561

3.  Epidemiologic, clinical, diagnostic and therapeutic aspects of visceral leishmaniasis in renal transplant recipients: experience from thirty cases.

Authors:  Avelar Alves de Silva; Álvaro Pacheco e Silva Filho; Ricardio de Castro Cinta Sesso; Ronaldo de Matos Esmeraldo; Cláudia Maria Costa de Oliveira; Paula Frassinetti Fernandes; Rodrigo Alves de Oliveira; Leila Silveira Veira de Silva; Valencio Pereira de Carvalho; Carlos Henrique Nery Costa; Jesusmar Ximenes Andrade; Diana Marisa Barros da Silva; Roosevelt Valente Chaves
Journal:  BMC Infect Dis       Date:  2015-02-25       Impact factor: 3.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.